BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α_2B Antagonist

Area of Science:

• Cardiovascular Pharmacology
• Myocardial Infarction Research
• Drug Discovery and Development

Background:

• Early reperfusion is critical after acute myocardial infarction but can cause reperfusion injury.
• Microvascular dysfunction contributes to reperfusion injury.
• Alpha2B adrenergic receptors (α2B-AR) are implicated in this process.

Purpose of the Study:

• To investigate the role of α2B-AR in reperfusion injury.
• To identify and optimize a novel α2B-AR antagonist for therapeutic use.

Main Methods:

• High-throughput screening (HTS) identified an initial α2B-AR antagonist.
• Lead optimization focused on improving selectivity, solubility, and safety, resulting in BAY-6096.
• Pharmacological evaluation in rats assessed BAY-6096's efficacy against an α2B-AR agonist.

Main Results:

• BAY-6096 was developed as a potent, selective, and highly water-soluble α2B-AR antagonist.
• Chemical modifications, including a pyridinium moiety and amide inversion, enhanced solubility and prevented genotoxicity.
• BAY-6096 dose-dependently inhibited α2B-AR agonist-induced hypertension in rats, confirming α2B-AR's role in vasoconstriction.

Conclusions:

• BAY-6096 is a promising therapeutic candidate for mitigating reperfusion injury.
• Targeting α2B-AR represents a viable strategy to improve outcomes following myocardial infarction.
• The developed compound validates the role of α2B receptors in vascular regulation.